QuiaPEG Pharmaceuticals Holding AB (publ)erhåller s.k. ”Notice of Allowance”om beviljande av patent I USA.


At the board meeting of the company held on April 26, 2018 the board of directors of QuiaPEG resolved, based on its authorization, to issue 6 000 000 warrants without consideration to the Dutch investment group, Nyenburgh Holding B.V. Each warrants provides entitlement to subscription of 1 new share in QuiaPEG with a quotient value of SEK 0.9, which means that the share capital can increase by a maximum of SEK 5 400 000 upon full exercise of the warrants through subscription of a maximum of 6 000 000 new shares. The warrants may be exercised for subscription of shares in the Company during the period from and including the day of issue of the warrants up to and including April 30, 2021. The subscription rate per share shall amount to SEK 3,50. The issue of the warrants is now registered.


Vid styrelsemöte i bolaget den 26 april 2018 beslutade styrelsen i QuiaPEG, baserat på sitt bemyndigande, om emission av 6 000 000 teckningsoptioner utan vederlag till den holländska investerargruppen Nyenburgh Holding B.V. Varje teckningsoption berättigar till nyteckning av 1 aktie i QuiaPEG med ett kvotvärde om 0,9 kronor, innebärande att aktiekapitalet kan ökas med högst 5 400 000 kronor vid fullt utnyttjande av teckningsoptionerna genom teckning av högst 6 000 000 nya aktier.


The shareholders of QuiaPEG Pharmaceuticals Holding AB (publ) have held an extraordinaryshareholders’meeting on June 29, 2018.The shareholders’ meeting resolved to, among othersthings, in accordance with the board ofdirectors’proposal, introduce an incentive program by way of issue of a maximum of 1 000 000 warrants to the wholly-owned subsidiary QuiaPEG Pharmaceuticals AB and to authorize the transfer of such warrants to management and others key personnel in the company and its subsidiary. The warrants are issued without consideration.

QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message